Long-term efficacy, safety, and inhibition of joint destruction by adalimumab in psoriatic arthritis: Results from ADEPT

被引：0
|
作者：
Mease, Philip J.
Gladman, Dafna
Ritchlin, Christopher
Sasso, Eric
机构：
[1] Swedish Med Ctr, Seattle, WA USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA
[4] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2007年 / 127卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
104
引用
收藏
页码：1820 / 1820
页数：1
相关论文
共 50 条
  • [41] Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 Weeks
    Fleischmann, Roy
    Song, In-Ho
    Enejosa, Jeffrey
    Mysler, Eduardo
    Bessette, Louis
    Durez, Patrick
    Ostor, Andrew
    Swierkot, Jerzy
    Song, Yanna
    Genovese, Mark
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [42] LONG-TERM SAFETY AND EFFECTIVENESS OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 72 WEEKS
    Ostor, Andrew
    Fleischmann, Roy
    Song, In-Ho
    Enejosa, Jeffrey
    Mysler, Eduardo
    Bessette, Louis
    Durez, Patrick
    Swierkot, Jerzy
    Song, Yanna
    Genovese, Mark
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 39 - 39
  • [43] Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
    Chimenti, Maria Sole
    Triggianese, Paola
    Narcisi, Alessandra
    Marinari, Barbara
    Teoli, Miriam
    Faleri, Sara
    Arcese, Annalisa
    Perricone, Roberto
    Costanzo, Antonio
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2016, 44 : 48 - 52
  • [44] Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
    Kivelevitch, Dario
    Mansouri, Bobbak
    Menter, Alan
    BIOLOGICS-TARGETS & THERAPY, 2014, 8 : 169 - 182
  • [45] Long-term efficacy and safety of apremilast in psoriatic arthritis: Focus on skin manifestations and special populations
    Balato, Anna
    Campione, Elena
    Cirillo, Teresa
    Malara, Giovanna
    Trifiro, Caterina
    Bianchi, Luca
    Fabbrocini, Gabriella
    DERMATOLOGIC THERAPY, 2020, 33 (03)
  • [46] Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
    Philip J. Mease
    Herbert Kellner
    Akimichi Morita
    Alan J. Kivitz
    Stella Aslanyan
    Steven J. Padula
    Andrew S. Topp
    Ann Eldred
    Frank Behrens
    Kim A. Papp
    Rheumatology and Therapy, 2022, 9 : 1361 - 1375
  • [47] Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
    Mease, Philip J.
    Kellner, Herbert
    Morita, Akimichi
    Kivitz, Alan J.
    Aslanyan, Stella
    Padula, Steven J.
    Topp, Andrew S.
    Eldred, Ann
    Behrens, Frank
    Papp, Kim A.
    RHEUMATOLOGY AND THERAPY, 2022, 9 (05) : 1361 - 1375
  • [48] Long-Term, Real-World Safety of Adalimumab in Rheumatoid Arthritis
    Harrold, Leslie R.
    Griffith, Jenny
    Litman, Heather J.
    Gershenson, Bernice
    Islam, Syecl
    Barr, Christine J.
    Guo, Dianlin
    Zueger, Patrick
    Fay, Jonathan
    Greenberg, Jeffrey
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [49] Concurrent efficacy of adalimumab against skin and joint disease in psoriatic arthritis
    Ritchlin, Christopher
    Mease, Philip J.
    Sasso, Eric
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (07) : 1819 - 1819
  • [50] Effect of immunogenicity on efficacy of long-term treatment of rheumatoid arthritis with adalimumab
    Jani, Meghna
    Chinoy, Hector
    Warren, Richard
    Griffiths, Christopher
    Barton, Anne
    LANCET, 2014, 383 : 60 - 60
12345